Gymnemic Acids: A Comprehensive Reference
1. Identity: Botanical Source, Chemical Classification, and Preparations
1.1 Botanical Source
Gymnemic acids are a class of chemical compounds isolated from the leaves of Gymnema sylvestre (Apocynaceae). It is a large tropical liana native to central and western India and can also be found in tropical Africa and in Australia. Distribution is worldwide, and it is recognized in the traditional medicine of many countries including Australia, Japan, and Vietnam. The leaves are most commonly used, but the stem also appears to have some drug action.
The plant is known by a wide range of common and regional names. Scientific synonyms and common names include Gymnema inodum, Gymnema montanum, Periploca sylvestris; and vernacular names such as Gurmar, Gurmarbooti, Kogilam, Madhunashini, Meshashringi, Meshavalli, Miracle plant, Periploca of the woods, Podapatri, Ram's horn, Sarkaraikolli, Shardunika, Sirukurinja, and Vishani. In Hindi it is called Gurmar, meaning "sugar destroyer," a direct reference to its best-known effect: temporarily suppressing the ability to taste sweetness and helping reduce sugar cravings.
1.2 Chemical Classification and Structure
Chemically, gymnemic acids are triterpenoid glycosides. The central structure is the aglycone gymnemagenin (C30H50O6). This is adorned with a sugar such as glucuronic acid and with various ester groups. These variations give rise to the different gymnemic acids.
The structure of gymnemagenin (3β,16β,21β,22α,23,28-hexahydroxy-olean-12-ene), the sapogenin of the antisweet principles of Gymnema sylvestre, was established by X-ray analysis of a di-O-isopropylidene derivative. On the basis of this result, the structure of deacylgymnemic acid was elucidated as the 3-O-β-glucuronide from carbon-13 nuclear magnetic resonance spectra.
Gymnemic acids (GAs) mainly belong to oleanane and dammarene classes. Oleanane saponins are the principal GAs, whereas gymnemasaponins are mainly oleanane saponin types, and gymnemasides are dammarene saponin types.
More than 20 homologs of gymnemic acid are known. Gymnemic acid I has the highest anti-sweet properties.
The anti-sweet acyl groups are critical to activity: the active constituents appear to be the gymnemic acids, a group of at least nine triterpene glycosides. Deletion of the acyl group diminishes the antisweet activity.
Showing the strongest SGLT1 inhibitory effect among 26 medicinal herbs screened, the phytochemicals extracted from Gymnema sylvestre (Retz.) Schult were identified as 3-O-β-D-glucuronopyranosyl-21-O-2-tigloyl-22-O-2-tigloyl gymnemagenin and 3-O-β-D-glucuronopyranosyl-21-O-2-methylbutyryl-22-O-2-tigloyl gymnemagenin by LC-MS/MS, UPLC-TOF/MS, and 1D/2D-NMR experiments.
Chemical analyses of Gymnema sylvestre leaf have demonstrated more than 50 components, the most distinctive being multiple gymnemic acids that are triterpene saponins. Other components include flavones, anthraquinones, alkaloids, phytin, resins, and tannins.
1.3 Isolation and Fractionation
The anti-diabetic array of molecules has been identified as a group of closely related gymnemic acids after successful isolation and purification from the leaves of G. sylvestre. The phytoconstituents of G. sylvestre were subsequently isolated and their chemistry and structures studied and elucidated in a series of investigations from 1965 through the early 1990s.
Aqueous extracts of the leaf of G. sylvestre are used for the isolation of GAs I–VI; the saponin fraction yields GAs XV–XVIII; and gymnemagenin is fractionated as GAs VIII–XII. Five antisweet principles — gymnemic acid-III, -IV, -V, -VIII, and -IX — were isolated in pure states from the hot water extract of leaves of Gymnema sylvestre. Of these, three (GA-III, -IV, and -V) were previously known, while two (GA-VIII and -IX) were new compounds. The structures of GA-VIII and -IX were elucidated as 3'-O-β-D-arabino-2-hexulopyranosyl gymnemic acid-III and -IV, respectively.
1.4 Common Commercial Forms and Preparations
Dietary supplements and teas that contain gymnema are usually made from the leaves that grow on the vine. Commercial preparations are most commonly standardized to a defined percentage of gymnemic acids; clinical studies investigating antidiabetic effects have typically used 200 or 400 mg extract daily standardized to contain 25% gymnemic acids. A separate standardization level is also used in practice: gymnema is also taken at a dosage of 400 to 600 milligrams daily of an extract standardized to contain 24 percent gymnemic acid.
The plant has also been consumed as a traditional leaf preparation and tea. In Japan, 50 tons of G. sylvestre leaves are consumed annually for the purpose of weight loss.
2. Traditional and Historical Use
2.1 Ayurvedic and South Asian Medicine
It is an Ayurvedic herb used for at least 2,000 years for the treatment of sugar diabetes. Native to the forests of India, Gymnema sylvestre (also called gurmar) has a coincidental double relationship to sugar: when placed on the tongue, it blocks the sensation of sweetness, and when taken internally, it might help control blood sugar levels in people with diabetes.
The earliest mention appears in the ancient Charaka Samhita (circa 1000–200 BCE), where it is prescribed under the name Meṣaśṛṅgī for conditions described as "Madhumeha," a term now correlated with high blood sugar and excessive urination. Traditionally, Ayurveda uses dried and powdered leaves, and less commonly roots, in formulations to balance blood sugar and promote digestive health.
Shardunika, also known as Gymnema sylvestre, has been a staple of Ayurvedic medicine for over 2,000 years. Ayurveda traditionally used it to help manage diabetes, high cholesterol, and digestive complaints, attributing to it anti-inflammatory, antioxidant, and hypoglycaemic properties.
In Eastern and Ayurvedic medicine, G. sylvestre leaves and extracts have been used to treat eye diseases, allergies, constipation, cough, dental caries, obesity, stomach ailments, and viral infections. G. sylvestre has also been used as an antioxidant, antimicrobial, and aphrodisiac.
2.2 Traditional Leaf Chewing and Taste Modification
One unique aspect of Gymnema sylvestre's traditional usage is its association with sweetness suppression. In Ayurvedic practices, chewing gymnema leaves was believed to temporarily hinder the ability to taste sweetness. They are anti-sweet compounds, or sweetness inhibitors. After chewing the leaves, solutions sweetened with sugar taste like water.
2.3 Early Scientific Investigation
Practitioners of Ayurveda, India's traditional medicine, first used gymnema to treat diabetes almost two thousand years ago. In the 1920s, preliminary scientific studies found some evidence that gymnema leaves could reduce blood sugar levels, but nothing much came of this observation for decades. Research in India picked up again in the 1980s and 1990s, leading to the publication of promising preliminary studies in people.
As early as 1930, the effects of the plant were investigated scientifically. The herb is traditionally used for the treatment of diabetes in India, and gymnema extracts are sold in Japan for the control of obesity.
3. Key Constituents and Mechanisms of Action
3.1 Sweet-Taste Receptor Inhibition
Gymnemic acids are triterpene glycosides that selectively suppress taste responses to various sweet substances in humans but not in mice. The molecular basis of this human-specific effect has been characterized. Research using a sweet taste receptor assay in transiently transfected HEK293 cells showed that application of gymnemic acids inhibited intracellular calcium responses to sweet compounds in HEK293 cells expressing human TAS1R2+TAS1R3, but not in those expressing the mouse sweet receptor Tas1r2+Tas1r3.
Gymnemic acids and glucuronic acid inhibited the human sweet receptor T1R2+T1R3. The interaction between transmembrane domains of human T1R3 and the glucuronosyl group of gymnemic acids is mainly required for the sweet-suppressing effect.
This sweet-suppressing effect of gymnemic acids is diminished by rinsing the tongue with γ-cyclodextrin (γ-CD). It suppresses the sweetness of most sweeteners, including intense artificial sweeteners such as aspartame and natural sweeteners such as thaumatin, a sweet protein.
3.2 Inhibition of Intestinal Glucose Transporters
Among extracts prepared from 26 medicinal herbs screened for their inhibitory activity on sodium-dependent glucose transporter 1 (SGLT1) by two-electrode voltage-clamp recording in Xenopus laevis oocytes, Gymnema sylvestre showed by far the strongest SGLT1 inhibitory effect, with the active phytochemicals identified as two specific gymnemagenin glucuronopyranosyl derivatives. Several studies suggest that gymnemic acids may act as antidiabetic agents by promoting regeneration of islet cells and increasing insulin secretion. Gymnemic acids have also been reported to inhibit glucose absorption from the intestine and to utilize glucose by enhancing the activities of enzymes in insulin-dependent pathways.
3.3 Alpha-Glucosidase and Alpha-Amylase Inhibition
A triterpene glycoside fraction isolated and purified from ethanolic extract of Gymnema sylvestre was investigated for blood glucose control using in vitro methods. The HPLC-purified active fraction exhibited effective inhibition of yeast α-glucosidase, sucrase, maltase, and pancreatic α-amylase with IC50 values of 3.16 ± 0.05 μg/mL, 74.07 ± 0.51, 5.69 ± 0.02, and 1.17 ± 0.24 μg/mL, respectively. This fraction was characterized to be a mixture of triterpene glycosides: gymnemic acids I, IV, and VII, and gymnemagenin.
An in vitro study found that the extract of G. sylvestre exhibited significant inhibitory activity against α-glucosidase with an IC50 of 68.70 ± 1.22 μg/mL, compared to acarbose (positive control) at 59.03 ± 2.30 μg/mL, indicating potential anti-diabetic activity.
3.4 Pancreatic Beta-Cell Stimulation and Insulin Secretion
Gymnemic acids have a wide array of medicinal applications, including as stimulators of pancreatic β-cells and inhibitors of α-glucosidase enzyme. Gymnemic acids are thought to be responsible for the antidiabetic activity of G. sylvestre; gymnemic acid VIII was the major component of an extract shown to stimulate insulin release from the pancreas.
In vitro studies using mouse pancreatic β-cell lines (MIN6) showed that the gymnemic acid-containing fraction did not exhibit any toxic effects on β-cell viability and showed protection against H2O2-induced ROS generation. There was up to a 1.34-fold increase in glucose-stimulated insulin secretion (p<0.05) in a dose-dependent manner relative to standard antidiabetic drug glibenclamide.
Gymnemic acids lower blood glucose concentrations in diabetic patients, stimulate insulin production and its signal transduction, lessen endoplasmic reticulum stress, and attenuate inflammation and insulin resistance via PPAR-δ and NFκB-mediated signaling pathways.
3.5 Liver X Receptor Antagonism and Lipid Metabolism
Deep pharmacological investigation demonstrated that gymnestrogenin, reducing the expression of SREBP1c and ABCA1 in vitro, is able to decrease lipid accumulation in HepG2 cells. The antagonistic effect of liver X receptor (LXR-α and LXR-β) and gymnemic acid isolates was evaluated using HepG2 cells. The outcomes revealed that GA inhibited LXR-β, whereas gymnestrogenin inhibited both LXR-α and LXR-β.
Gymnemic acid — an active component isolated from Gymnema sylvestre — has anti-obesity and antidiabetic properties, decreases body weight, and also inhibits glucose absorption. Several components extracted from Gymnema prevent the accumulation of triglycerides in muscle and liver, and also decrease fatty acid accumulation in the circulation.
3.6 Endoplasmic Reticulum Stress Modulation
GA was shown to downregulate the expression of endoplasmic reticulum (ER) stress by improving signaling proteins, minimizing the effect of p-IRS-1 (Ser), and maximizing p-IRS-1 (tyr) signaling. These findings confirm the controlling effects of GA against type 2 diabetes mellitus.
4. Scientific Evidence by Area of Use
4.1 Glycemic Control in Type 2 Diabetes Mellitus
Systematic review and meta-analysis evidence: A systematic review and meta-analysis aimed at finding the effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes mellitus (T2DM) searched PubMed, Cochrane Library, Google Scholar, and Science Direct through June 2020. The meta-analysis consisting of 10 studies with a total of 419 participants showed that GS supplementation significantly reduced fasting blood glucose (FBG) (SMD 1.57 mg/dl, 95% CI 2.22 to −0.93, p < .0001, I2 90%), postprandial blood glucose (PPBG) (SMD 1.04 mg/dl, 95% CI 1.53 to −0.54, p < .0001, I2 80%), and glycated haemoglobin (HbA1c) (SMD 3.91, 95% CI 7.35 to −0.16%, p < .0001, I2 99%) compared to baseline.
Limitations: The very high heterogeneity values (I2 up to 99%) across all three glycemic outcomes indicate substantial variability between the included studies, limiting the strength of pooled conclusions. Limited clinical information is available to support the use of gymnema for any indication.
Key individual clinical trials:
In 1990, Baskaran et al. from India reported a study which included twenty-two patients with type 2 diabetes who were treated with oral anti-diabetics. The patients received the leaf extract of Gymnema sylvestre in a dose of 400 mg daily for 18–20 months. Improvement in glycemic control was associated with increased circulating insulin levels (24 ± 9 vs. 32 ± 6 U/mL, p<0.001) and a corresponding increase in C-peptide (298 ± 42 vs. 447 ± 48 pmol/L, p<0.05) in patients.
A study conducted on 58 patients with type 2 diabetes mellitus for 90 days resulted in the reduction of fasting (p < 0.005) and postprandial blood glucose levels (p < 0.001), along with a reduction of triglyceride (p < 0.05).
Clinical trials in humans have used Gymnema sylvestre at doses of 300 mg twice daily (total 600 mg/day) for patients with impaired glucose tolerance, resulting in significant reductions in 2-hour oral glucose tolerance test (OGTT) values, HbA1c, body weight, BMI, and LDL cholesterol, along with improved insulin sensitivity and a higher percentage of patients achieving normal HbA1c values.
Overall evidence strength: Preliminary to moderate. A good level of evidence (Grade B) for use in type 1 and type 2 diabetics has been noted; however, robust clinical trials are still lacking.
4.2 Glycemic Control in Type 1 Diabetes Mellitus
As early as 1990, Shanmugasundaram et al. from India reported a study which included 27 patients with insulin-dependent diabetes mellitus. They were treated with the leaf extract of Gymnema sylvestre at a dose of 400 mg daily. Treatment was associated with a decrease in insulin requirement and lowering of fasting blood sugar, glycosylated hemoglobin, and glycosylated plasma protein levels. Treatment was also associated with improvement in lipid profile. Control patients who did not receive Gymnema sylvestre did not show similar changes.
In another study, 64 individuals with type 1 diabetes were treated with gymnema leaf extract for 6 to 30 months, resulting in reduction of plasma glucose level, reduced external insulin dose, and significant reduction in HbA1c (p < 0.001).
One study included 27 patients with type 1 diabetes mellitus (DM1), aged 10 to 31 years and 44 to 50 years, with pre-study insulin monotherapy of 2 to 3 months. They were given 400 mg/day of Gymnema sylvestre over a period of 30 months as a complementary treatment for insulin therapy. Five evaluations were carried out during the intervention.
Evidence strength: These are small, unblinded studies conducted at a single center in India, without placebo control. Results are suggestive but must be interpreted with caution given methodological limitations.
4.3 Impaired Glucose Tolerance and Prediabetes
A study on 81 individuals (18–75 years old) with mildly impaired fasting blood glucose concentrations (98–125 mg/dL) was undertaken to investigate the tolerability of a food supplement based on Zea mays and Gymnema sylvestre extracts, zinc, and chromium. Subjects were randomized into three groups (27 in each group) and supplemented with one or two tablet(s)/day of the supplement, or two tablets/day of placebo, with blood sampling at baseline and after 3 months. Compared to placebo, FBG and glycated haemoglobin (HbA1c) were significantly (p < 0.001) reduced in the single-tablet group. At the doses of one and two tablet(s)/day, the supplement exerted no effect on other parameters examined. This study used a combination product, making it impossible to attribute the effects solely to gymnemic acids.
4.4 Sweet Taste Suppression and Craving Reduction
In vitro, gymnemic acids have been shown to bind to and inhibit human sweet taste receptors, and both animal and human studies indicate the ingredients can suppress taste response to sweet substances. This effect is well-documented at the molecular and physiological levels. Gymnema has become relatively well known for its ability to block some of the sugar receptors on the tongue, making foods taste less sweet. This effect may help reduce sugar cravings and also help people cut back on calories and sweet foods.
Evidence strength: The taste-blocking effect is among the most mechanistically well-characterized effects of gymnemic acids, with consistent findings from in vitro receptor studies, animal models, and human observation. Large controlled trials on downstream effects (caloric intake, weight loss) remain limited.
4.5 Lipid-Lowering Effects
Clinical investigations on Gymnema sylvestre revealed its potential to reduce body weight and glucose levels, triglyceride, LDL-c, and total cholesterol, and to elevate the amount of insulin and C-peptide available in blood.
A randomized controlled clinical trial on 75 patients with T2DM evaluated the effects of a combination of myo-inositol and d-chiro-inositol (40:1), α-lactalbumin, Gymnema sylvestre, and zinc on glucose and lipid profile. The intention-to-treat analysis displayed no significant differences in glucose parameters between groups; however, the study group displayed reduced levels of total cholesterol (p = 0.01) and LDL (p = 0.03) after 3 months of supplementation. A subgroup analysis involving patients who did not modify their antidiabetic therapy showed, after 6 months, improved levels of total cholesterol (p = 0.03) and LDL (p = 0.04) in the study group versus placebo, along with a greater body weight reduction (p = 0.03) after 3 months. Furthermore, levels of HDL (p = 0.03) and triglycerides (p = 0.04) improved within the study group.
Evidence strength: Preliminary. Most lipid data come from combination-product trials or animal studies, and direct human evidence attributable solely to gymnemic acids is limited. Use as a lipid-lowering agent, for weight loss, and for the inhibition of caries have been investigated, primarily in rodent studies.
4.6 Obesity and Body Weight
Gymnemic acid, an active component isolated from Gymnema sylvestre, has anti-obesity and anti-diabetic properties by decreasing body weight and inhibiting glucose absorption. Early research suggests that taking a specific combination of Gymnema sylvestre extract, hydroxycitric acid, and niacin-bound chromium by mouth for 8 weeks might reduce body weight in people who are overweight or obese.
Evidence strength: Weak for body weight as an isolated endpoint. Available clinical data use combination products; effects attributable to gymnemic acids alone cannot be isolated from these trials.
4.7 Antioxidant and Anti-Inflammatory Properties
Gymnema extracts may have other antidiabetic actions, such as enhanced insulin secretion and inhibition of glucose absorption, as well as cholesterol-lowering, antioxidant, anti-inflammatory, antibacterial, and antineoplastic activities. Gymnemic acids further possess numerous biological properties, such as lipid-lowering, antimicrobial, antioxidative, and antidiabetic activities.
Evidence strength: Largely preclinical (in vitro and animal). Human evidence for these properties as independent endpoints is not yet established.
5. Body Systems and Health Areas of Association
- Endocrine / Metabolic system: Glycemic control in both type 1 and type 2 diabetes mellitus, stimulation of pancreatic β-cells and insulin secretion, inhibition of intestinal glucose absorption via SGLT1.
- Gustatory / Sensory system: Suppression of sweet taste perception via inhibition of the human TAS1R2+TAS1R3 receptor complex.
- Cardiovascular / Lipid metabolism: Reduction of total cholesterol, LDL-cholesterol, triglycerides; elevation of HDL in clinical combination studies.
- Gastrointestinal system: Inhibition of α-glucosidase and α-amylase; traditional use for digestive ailments.
- Hepatic system: In vitro LXR antagonism and potential hepatoprotective properties in animal models; one published case report of hepatotoxicity (attribution uncertain).
- Inflammatory pathways: Modulation of PPAR-δ and NFκB-mediated signaling (preclinical evidence).
- Body weight: Associated with reduced caloric intake (via taste suppression) and decreasing triglyceride accumulation in tissues, primarily in animal and combination-product studies.
6. Dosage Forms and Reported Dosages
Clinical studies investigating antidiabetic effects have typically used 200 or 400 mg extract daily standardized to contain 25% gymnemic acids. A total daily dose of 500 to 1,000 mg/day of leaf extract given in twice daily divided doses has also been administered for a duration of 2 or 3 months in clinical trials.
Gymnema is also reported to be taken at a dosage of 400 to 600 milligrams daily of an extract standardized to contain 24 percent gymnemic acid.
In the landmark type 1 and type 2 diabetes studies from India, the leaf extract of Gymnema sylvestre was administered at a dose of 400 mg daily. Clinical trials in patients with impaired glucose tolerance have used doses of 300 mg twice daily (total 600 mg/day).
Preparations commercially available include standardized leaf extracts in capsule and tablet form, loose dried leaf, leaf powder, and herbal teas. Standard doses used in clinical studies range from 200–400 mg of standardized extract (75% gymnemic acids) per day, typically divided into two doses with meals.
7. Safety Considerations and Interactions
7.1 General Safety Profile
Limited evidence from toxicological in vivo studies and human clinical studies suggested a lack of relevant adverse effects of this botanical. However, human studies provided some indications that certain Gymnema extracts may enhance the glucose-lowering effects of certain antidiabetic drugs.
7.2 Hypoglycemia Risk
Considering the uncertainties for the composition of different Gymnema preparations, potential herb–drug interactions, and the indications of glucose-lowering or hypoglycaemic effects, the use of Gymnema-based food supplements in combination with authorised antidiabetic drugs may be associated with risks.
7.3 Hepatotoxicity: A Published Case Report
A 60-year-old woman developed weakness, fatigue, loss of appetite, weight loss, and jaundice 7 days after starting Gymnema sylvestre in the form of an herbal tea, taken three times daily for type 2 diabetes. After 3 days of symptoms, she stopped the herbal tea, and a week later sought medical care due to worsening symptoms. She had no history of liver disease, alcohol abuse, risk factors for viral hepatitis, or drug allergies. Her only other medication was acetazolamide for glaucoma, taken for two years. Laboratory tests revealed a bilirubin of 15.6 mg/dL (direct 9.0), ALT 760 U/L, AST 657 U/L, alkaline phosphatase 160 U/L, and GGT 273 U/L (R=16). Tests for acute hepatitis A, B, C, and E were negative, as were autoantibodies.
This published case report of liver toxicity related to consumption of a Gymnema tea could point to potential adulteration or contamination of the tea with hepatotoxic substances, or to a hepatotoxic potential of certain G. sylvestre constituents. However, in the light of preliminary evidence from animal studies, rather potential hepatoprotective effects of Gymnema preparations were observed.
There have been isolated rare reports of liver injury from herbal products containing Gymnema sylvestre, but attribution to the herb was usually weak. A description of an online compendium of cases of liver toxicity attributed to herbal and dietary supplement products does not list or discuss Gymnema sylvestre.
7.4 Pregnancy and Lactation
Information regarding safety and efficacy in pregnancy and lactation is lacking.
7.5 Drug Interactions
Human studies provided some indications that certain Gymnema extracts may enhance the glucose-lowering effects of certain antidiabetic drugs. Considering the uncertainties for the composition of different Gymnema preparations, potential herb–drug interactions, and the indications of glucose-lowering or hypoglycaemic effects, the use of Gymnema-based food supplements in combination with authorised antidiabetic drugs may be associated with risks.
Human studies provided some indications that certain Gymnema extracts may enhance the glucose-lowering effects of certain antidiabetic drugs. Considering the uncertainties for the composition of different Gymnema preparations, potential herb–drug interactions, and the indications of glucose-lowering or hypoglycaemic effects, the use of Gymnema-based food supplements in combination with authorised antidiabetic drugs may be associated with risks.
7.6 Overall Evidence Limitations
Several trials of Gymnema extracts in humans have shown mild decreases in fasting plasma glucose levels, but the overall evidence base remains limited in scope and quality. Most published trials are small, unblinded, or lack adequate placebo controls. High heterogeneity across meta-analyses further limits interpretability. Significant variation in extract standardization, gymnemic acid content, and preparation method between commercial and research-grade products also complicates direct comparisons across studies.
References
Go back